Agomab reports Crohn’s trial extension data
Compartilhar
Agomab (NASDAQ:AGMB) reported topline results from the STENOVA open-label extension study of ontunisertib in patients with fibrostenosing Crohn’s disease, with 49 patients completing the 48-week extension period.
